Sugammadex did not increase pulmonary, cardiovascular, or mortality risks compared with neostigmine in severe CKD patients undergoing elective gastrointestinal surgery.
Does sugammadex reduce the risk of pulmonary, cardiovascular, or mortality outcomes compared to neostigmine in patients with severe CKD having elective gastrointestinal surgery?
In patients with severe CKD undergoing elective GI surgery, sugammadex does not significantly increase short-term pulmonary, cardiovascular, or mortality risks compared to neostigmine.
Sugammadex was not associated with a significantly increased risk of pulmonary, cardiovascular, or mortality outcomes compared with neostigmine in patients with severe CKD having elective gastrointestinal surgery. Given the potential residual confounding by unmeasured factors such as surgical complexity, randomized controlled trials are needed to confirm these findings.
Hung et al. (2026) studied this question. Sugammadex did not increase pulmonary, cardiovascular, or mortality risks compared with neostigmine in severe CKD patients undergoing elective gastrointestinal surgery.